WuXi AppTec H1 Revenue Up 38.9% to RMB 28.9 Billion, Raises Full-Year Guidance

WuXi AppTec disclosed its half-year results in August 2026. During the reporting period, the company achieved total revenue of RMB 28.9 billion, up 38.9% year on year, and net profit attributable to shareholders of RMB 11.08 billion, up 29.4% — the first time the company's half-year net profit surpassed RMB 10 billion. Excluding the impact of non-recurring gains from the partial divestment of an associate in 2025, attributable net profit for the first half grew by nearly 90%. In its interim report, the company said growth was driven mainly by the greater success of several customer products and its CRDMO model, and it raised its full-year guidance, lifting the 2026 revenue target from RMB 51.3-53.0 billion set at the start of the year to RMB 58.5-60.5 billion.

From an industry perspective, of the 238 new drugs approved by the U. S. Food and Drug Administration between 2021 and 2025, 165 (69.3%) were new molecular entities, covering traditional small molecules, peptides and nucleic acids. Over the five-year period, small molecules accounted for no less than 59% of annual approvals, and exceeded 70% in 2021, 2023 and 2025. Small molecules can cross the blood-brain barrier and cell membranes, target intracellular targets and support oral administration, giving them distinctive advantages across clinical scenarios. Peptide and oligonucleotide drugs have grown on the back of technological breakthroughs, and the commercial application of GLP-1 class drugs has further expanded the scope of chemically synthesized drugs.

WuXi AppTec, through its CRDMO model, provides end-to-end services spanning drug discovery, process development and scaled manufacturing. The company operates six active pharmaceutical ingredient manufacturing bases globally, with more than 4 million liters of small-molecule reactor capacity and 120,000 square meters of GLP laboratory space, covering services from preclinical research and clinical trials to ton-scale commercial production. During the reporting period, the small-molecule D&M pipeline added 699 molecules in total, including 15 commercial and Phase III projects. D&M revenue reached RMB 14.99 billion, up 72.7% year on year, with second-quarter revenue of RMB 8.06 billion setting a quarterly record.

To expand capacity, WuXi AppTec brought forward construction of a new base in Changzhou in the first half of 2026, and raised its 2026 capital expenditure plan from RMB 6.5-7.5 billion to RMB 7.5-8.5 billion. As of the end of June 2026, the company's order backlog for continuing operations stood at RMB 66.43 billion, up 25.2% year on year.